SE0203410D0 - New use - Google Patents

New use

Info

Publication number
SE0203410D0
SE0203410D0 SE0203410A SE0203410A SE0203410D0 SE 0203410 D0 SE0203410 D0 SE 0203410D0 SE 0203410 A SE0203410 A SE 0203410A SE 0203410 A SE0203410 A SE 0203410A SE 0203410 D0 SE0203410 D0 SE 0203410D0
Authority
SE
Sweden
Prior art keywords
vomiting
inhibitor compound
proton pump
pump inhibitor
nausea
Prior art date
Application number
SE0203410A
Other languages
Swedish (sv)
Inventor
Ulrich Thissen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0203410A priority Critical patent/SE0203410D0/en
Publication of SE0203410D0 publication Critical patent/SE0203410D0/en
Priority to AU2003279667A priority patent/AU2003279667A1/en
Priority to PCT/SE2003/001774 priority patent/WO2004045612A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method for preventing postoperative nausea and vomiting in patients following anaesthesia by prophylaxis and/or treatment with a proton pump inhibitor compound. The proton pump inhibitor compound may be administered alone and/or in combination with other drugs, such as an 5-HT3 receptor antagonist and/or a corticosteriod. The method is also applicable more in general in patients on high risk of nausea and vomiting.
SE0203410A 2002-11-18 2002-11-18 New use SE0203410D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE0203410A SE0203410D0 (en) 2002-11-18 2002-11-18 New use
AU2003279667A AU2003279667A1 (en) 2002-11-18 2003-11-14 Use of a proton pump inhibitor for preventing postoperative nausea and vomiting
PCT/SE2003/001774 WO2004045612A1 (en) 2002-11-18 2003-11-14 Use of a proton pump inhibitor for preventing postoperative nausea and vomiting

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0203410A SE0203410D0 (en) 2002-11-18 2002-11-18 New use

Publications (1)

Publication Number Publication Date
SE0203410D0 true SE0203410D0 (en) 2002-11-18

Family

ID=20289602

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0203410A SE0203410D0 (en) 2002-11-18 2002-11-18 New use

Country Status (3)

Country Link
AU (1) AU2003279667A1 (en)
SE (1) SE0203410D0 (en)
WO (1) WO2004045612A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20070259933A1 (en) * 2006-05-04 2007-11-08 Xenoport, Inc. Compositions, dosage forms and methods of treating emesis
MX349677B (en) 2007-11-13 2017-08-08 Meritage Pharma Inc Corticosteroid compositions.
US20090131386A1 (en) 2007-11-13 2009-05-21 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8630080D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
GB9305593D0 (en) * 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists

Also Published As

Publication number Publication date
AU2003279667A1 (en) 2004-06-15
WO2004045612A8 (en) 2005-03-17
WO2004045612A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
EA200400966A1 (en) NEW MEDICATED FORMS OF SUBSTITUTED BENZIMIDAZOL AND METHOD OF THEIR APPLICATION
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
IS8502A (en) Azate cyclic heterocycles as cannabinoid receptor antagonists
GEP20094638B (en) Benzimidazolone carboxylic acid derivatives
IS8503A (en) Azate cyclic heterocycles as cannabinonide receptor antagonists
SG148202A1 (en) Quinazolinone compounds as anticancer agents
CY1109763T1 (en) MATERIALS AND METHOD FOR TREATMENT OF CELLULAR DISORDERS
DK1411932T3 (en) Combination therapy with substituted oxazolidinones
WO2006113498A3 (en) 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases
DK1565471T3 (en) Quionolinylpyrazoles
MX2007006066A (en) Jnk inhibitors for treatment of cns injury.
WO2004006859A3 (en) Platinum compound
HK1121936A1 (en) Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
EA200600223A1 (en) SUBSTITUTED 2-AMINOTHETRALINES FOR THE TREATMENT OF DEPRESSION
WO2004017896A3 (en) Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
MXPA05007379A (en) Method of treating nausea, vomiting, retching or any combination thereof.
WO2007105113A3 (en) Use of crf1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
DE60322417D1 (en) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1,8-naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
MX2010010334A (en) Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsu lfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide.
NO20072832L (en) Painkiller
SE0203410D0 (en) New use
IS7517A (en) Compounds used in the treatment of anthrax and prevent lethal effects
WO2008032222A3 (en) Treatment of vertigo with acetyl-l-leucine
CA2540102A1 (en) A combination of candesartan and rosuvastatin for the treatment of atherosclerosis
BRPI0507802A (en) compound, composition, and method for treating inflammation or a metabolic disorder